Posted by Michael Wonder on 25 Oct 2023
Mirikizumab for the treatment of patients with moderate to severe active ulcerative colitis
25 October 2023 - NICE has published final evidence-based recommendations on the use of mirikizumab (Omvoh) for the treatment of patients with moderate to severe active ulcerative colitis.
Mirikizumab is recommended as an option for the treatment of adults with moderate to severe active ulcerative colitis when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if:
- A tumour necrosis factor (TNF) alfa antagonist has not worked or
- A tumour necrosis factor (TNF) alfa antagonist cannot be tolerated or is not suitable and
- Eli Lilly provides it according to the commercial arrangement
